Markus Muller

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Martin Schostak1
Carsten Kempkensteffen1
Mark Schrader1
1Martin Schostak
1Carsten Kempkensteffen
1Mark Schrader
Learn More
  • Jens Kollermann, Carsten Kempkensteffen, Burkhard Helpap, Mark Schrader, Hans Krause, Markus Muller +2 others
  • 2006
BACKGROUND In spite of excellent cure rates for prostate cancer patients with favorable tumor characteristics, patients with unfavorable characteristics after radical prostatectomy are still at a significantly increased risk of tumor progression. Early adjuvant hormonal therapy (AHT) has been shown to be of prognostic benefit in these patients.(More)
  • 1